English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

We read the recent paper on profile of EBV-associated infectious mononucleosis (IM) by Balasubramanian, et al. [1] with interest. They concluded that EBV associated IM is more common in preschool children. Here we highlight another dreaded complication due to reactivation of EBV post-allogeneic stem cell transplant (SCT) leading to post-transplant lymphoproliferative disorder (PTLD). Mortality rates due to PTLD are reported to be as high as 50–90% [2]. Various therapeutic approaches are suggested for EBV-associated PTLD including anti-B-cell treatments such as rituximab (AntiCD20 monoclonal antibody) [3]. Rituximab alone or combined with low-dose chemotherapy is an effective therapy for EBV-associated PTLD [4,5]. We describe here successful treatment of EBV induced PTLD with rituximab in an infant post-allogeneic SCT.

EBV-reactivation and posttransplant lymphoproliferative disorder treated with rituximab